Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
GAITHERSBURG, Md., March 07, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report its fourth quarter and full year 2017 financial and operating results following the close of U.S. financial markets on Wednesday, March 14, 2018.
| Conference call and webcast details are as follows: | |
| Date: | March 14, 2018 |
| Time: | 5:00 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 6472939 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
| Conference call and webcast replay: | |
| Dates: | Starting at 8:00 p.m. ET, March 14, 2018 until |
| 9:00 p.m. ET March 21, 2018 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 6472939 |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until June 14, 2018 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Our RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of the Company’s efforts to improve global health. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investors
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
